BG104122A - 2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate - Google Patents

2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate

Info

Publication number: BG104122A
Authority: BG; Bulgaria
Prior art keywords: propylmercapto; trifluoromethylpyrimidin; tret; piperazin; pyrimidin
Prior art date: 1997-08-14

Application number

BG104122A

Other languages

Bulgarian (bg)

English (en)

Inventor

Stefan Blank

Dorothea Starck

Hans-Joerg Treiber

Stefan Koser

Bernd Schaefer

Marco Thyes

Thomas Hoeger

Original Assignee

Abbott Gmbh & Co. Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-08-14

Filing date

2000-02-03

Publication date

2000-11-30

2000-02-03 Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg

2000-11-30 Publication of BG104122A publication Critical patent/BG104122A/xx

Links

VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 title abstract 3
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 title abstract 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title abstract 2
150000003839 salts Chemical class 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000001530 fumaric acid Substances 0.000 abstract 1
239000003446 ligand Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/56—One oxygen atom and one sulfur atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

BG104122A 1997-08-14 2000-02-03 2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate BG104122A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19735410A DE19735410A1 (de)	1997-08-14	1997-08-14	2-{3-[4-(2-t-Butyl-6-trifluormethylpyrimidin-4-yl)piperazin-1-yl]propylmercapto}pyrimidin-4-ol-fumarat
PCT/EP1998/005178 WO1999009015A1 (fr)	1997-08-14	1998-08-14	Fumarate de 2-{3-(4-(2-t-butyl-6- trifluoromethylpyrimidin-4-yl) piperazin-1-yl] propylmercapto} pyrimidin-4-ol

Publications (1)

Publication Number	Publication Date
BG104122A true BG104122A (en)	2000-11-30

Family

ID=7839072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG104122A BG104122A (en)	1997-08-14	2000-02-03	2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate

Country Status (25)

Country	Link
US (1)	US20010020022A1 (fr)
EP (2)	EP1003728B1 (fr)
JP (1)	JP4444492B2 (fr)
KR (1)	KR100571945B1 (fr)
CN (1)	CN1267286A (fr)
AR (1)	AR016605A1 (fr)
AT (1)	ATE525362T1 (fr)
AU (1)	AU749575B2 (fr)
BG (1)	BG104122A (fr)
BR (1)	BR9811177A (fr)
CA (1)	CA2301297A1 (fr)
CO (1)	CO4960663A1 (fr)
DE (1)	DE19735410A1 (fr)
ES (1)	ES2374156T3 (fr)
HU (1)	HUP0003710A3 (fr)
ID (1)	ID24639A (fr)
IL (1)	IL134246A (fr)
NO (1)	NO314935B1 (fr)
NZ (1)	NZ502675A (fr)
PL (1)	PL201927B1 (fr)
SK (1)	SK1182000A3 (fr)
TR (1)	TR200000406T2 (fr)
TW (1)	TW467912B (fr)
WO (1)	WO1999009015A1 (fr)
ZA (1)	ZA987239B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE402704T1 (de) *	2000-03-27	2008-08-15	Abbott Gmbh & Co Kg	Dopamin-d3-rezeptor-liganden zur behandlung von sucht
DE10101307A1 (de) *	2001-01-12	2002-08-01	Fumapharm Ag Muri	Fumarsäurederivate als NF-kappaB-Inhibitor
DE102004027358A1 (de)	2004-06-04	2005-12-29	Abbott Gmbh & Co. Kg	Pyrimidinverbindungen und ihre Verwendung
ES2340941T3 (es) *	2004-08-09	2010-06-11	ABBOTT GMBH & CO. KG	Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
CN102887860B (zh) *	2012-09-29	2015-07-01	上海泰坦科技有限公司	4-氯-6-三氟甲基嘧啶类化合物的制备方法
US9598387B2 (en)	2012-10-11	2017-03-21	Southern Research Institute	Urea and amide derivatives of aminoalkylpiperazines and use thereof
US9376396B2 (en)	2012-10-22	2016-06-28	AbbVie Deutschland GmbH & Co. KG	Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4425143A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Substituierte Pyrimidinverbindungen und deren Verwendung

1997
- 1997-08-14 DE DE19735410A patent/DE19735410A1/de not_active Withdrawn
1998
- 1998-08-12 AR ARP980103980A patent/AR016605A1/es not_active Application Discontinuation
- 1998-08-12 TW TW087113230A patent/TW467912B/zh not_active IP Right Cessation
- 1998-08-13 CO CO98046527A patent/CO4960663A1/es unknown
- 1998-08-13 ZA ZA9807239A patent/ZA987239B/xx unknown
- 1998-08-14 HU HU0003710A patent/HUP0003710A3/hu unknown
- 1998-08-14 EP EP98946343A patent/EP1003728B1/fr not_active Expired - Lifetime
- 1998-08-14 SK SK118-2000A patent/SK1182000A3/sk unknown
- 1998-08-14 EP EP10179278A patent/EP2272833A1/fr not_active Withdrawn
- 1998-08-14 IL IL13424698A patent/IL134246A/en not_active IP Right Cessation
- 1998-08-14 ID IDW20000266A patent/ID24639A/id unknown
- 1998-08-14 AU AU93426/98A patent/AU749575B2/en not_active Ceased
- 1998-08-14 BR BR9811177-9A patent/BR9811177A/pt not_active IP Right Cessation
- 1998-08-14 ES ES98946343T patent/ES2374156T3/es not_active Expired - Lifetime
- 1998-08-14 JP JP2000509698A patent/JP4444492B2/ja not_active Expired - Lifetime
- 1998-08-14 CN CN98808156A patent/CN1267286A/zh active Pending
- 1998-08-14 NZ NZ502675A patent/NZ502675A/en not_active IP Right Cessation
- 1998-08-14 PL PL338603A patent/PL201927B1/pl unknown
- 1998-08-14 WO PCT/EP1998/005178 patent/WO1999009015A1/fr not_active Ceased
- 1998-08-14 TR TR2000/00406T patent/TR200000406T2/xx unknown
- 1998-08-14 KR KR1020007001435A patent/KR100571945B1/ko not_active Expired - Lifetime
- 1998-08-14 AT AT98946343T patent/ATE525362T1/de active
- 1998-08-14 US US09/485,460 patent/US20010020022A1/en not_active Abandoned
- 1998-08-14 CA CA002301297A patent/CA2301297A1/fr not_active Abandoned
2000
- 2000-02-03 BG BG104122A patent/BG104122A/xx unknown
- 2000-02-10 NO NO20000665A patent/NO314935B1/no unknown

Also Published As

Publication number	Publication date
EP2272833A1 (fr)	2011-01-12
AU9342698A (en)	1999-03-08
PL338603A1 (en)	2000-11-06
HUP0003710A3 (en)	2002-01-28
TR200000406T2 (tr)	2000-05-22
PL201927B1 (pl)	2009-05-29
JP4444492B2 (ja)	2010-03-31
KR20010022833A (ko)	2001-03-26
ES2374156T3 (es)	2012-02-14
WO1999009015A1 (fr)	1999-02-25
CO4960663A1 (es)	2000-09-25
IL134246A (en)	2002-11-10
CN1267286A (zh)	2000-09-20
ATE525362T1 (de)	2011-10-15
AR016605A1 (es)	2001-07-25
US20010020022A1 (en)	2001-09-06
SK1182000A3 (en)	2000-09-12
ID24639A (id)	2000-07-27
CA2301297A1 (fr)	1999-02-25
EP1003728B1 (fr)	2011-09-21
NO314935B1 (no)	2003-06-16
ZA987239B (en)	2000-02-14
NO20000665L (no)	2000-02-10
IL134246A0 (en)	2001-04-30
BR9811177A (pt)	2000-07-25
JP2001515070A (ja)	2001-09-18
AU749575B2 (en)	2002-06-27
HUP0003710A2 (hu)	2001-10-28
DE19735410A1 (de)	1999-02-18
KR100571945B1 (ko)	2006-04-18
EP1003728A1 (fr)	2000-05-31
NO20000665D0 (no)	2000-02-10
NZ502675A (en)	2001-06-29
TW467912B (en)	2001-12-11

Publication	Publication Date	Title
SI0955295T1 (en)	2004-10-31	Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines
ZA200205265B (en)	2003-11-11	A novel crystalline form of N-[4-[2-[2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]L-glutamic acid and process therefor.
GR3034969T3 (en)	2001-02-28	N-(aroyl)glycine hydroxamic acid derivatives and related compounds
CA2296604A1 (fr)	1999-01-28	Modification de la forme cristalline d'un derive n-phenyl-2-pyrimidineamine, procede de preparation et d'utilisation de ce dernier
MY114389A (en)	2002-10-31	Aqueous risperidone formulations
TR200000129T2 (tr)	2000-07-21	Yepyeni spiroazabisiklik heterosiklik bileşikler.
IL142011A0 (en)	2002-03-10	Stable concentrated insulin preparations for pulmonary delivery
CA2004747A1 (fr)	1990-06-07	Composes pharmaceutiques ayant une action sur le snc
EP1020461A3 (fr)	2006-10-04	Utilisation des sels alcalins de l'énantiomère (-) d'omeprazole
GEP20074171B (en)	2007-07-25	N,n'−substituted−1,3−diamino−2−hydroxypropane derivatives
WO2002000209A3 (fr)	2003-01-16	Analogues de gabapentine pour traiter les troubles du sommeil
HRP20010584B1 (en)	2010-08-31	N-[2-hydroxy-3-(1-piperidinyl)propoxy]pyridine-1-oxide-3-carboximidoyl chloride and its use in the treatment of insulin resistance
JO2321B1 (en)	2005-09-12	4-phenyl-pyridine derivatives
AU1562988A (en)	1988-11-10	DNA clone of human thrombomodulin
BG104122A (en)	2000-11-30	2-{3-[4-(2-tret.-butyl-6-trifluoromethylpyrimidin-4-yl)piperazin-1 -yl]propylmercapto}pyrimidin-4-ol fumarate
TW223061B (en)	1994-05-01	9-(3-cyanophenyl)-3,4,6,7,9,10-hexahydro-1,8-(2h,5h)-acridinedione and pharmaceutical compositions containing same
ZA89389B (en)	1989-10-25	Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
IT1222395B (it)	1990-09-05	Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
IL162314A0 (en)	2005-11-20	Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
MY103210A (en)	1993-05-29	Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
AU5781298A (en)	1998-08-26	Wettable or water-soluble granular agrochemical composition
IL115334A0 (en)	1995-12-31	Quinoxaline derivatives useful in therapy
TW349864B (en)	1999-01-11	Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
AU3749195A (en)	1996-05-06	Bis-2-aminopyridines, preparation method therefor and use tereof for controlling parasitic infections
GR3023896T3 (en)	1997-09-30	2,3,4,5-tetrahydro-1h-3-benzazepines and pharmaceutically acceptable acid addition salts thereof.